G. F. Fleming

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? (2008)

Regan, M. M., Pagani, O., Walley, B., Torrisi, R., Perez, E. A., Francis, P., ...

Background: The role of chemotherapy in addition to combined endocrine therapy for premenopausal women with endocrine-responsive early breast cancer remains an open question, yet trials designed to...

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study (2004)

Fleming, G. F., Filiaci, V. L., Bentley, R. C., Herzog, T., Sorosky, J., Vaccarello, L., ...

Background: This study was performed to determine whether 24-h paclitaxel plus doxorubicin and filgrastim was superior to cisplatin plus doxorubicin in patients with endometrial cancer with respect...

Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction (2003)

Fleming, G. F., Schilsky, R. L., Schumm, L. P., Meyerson, A., Hong, A. M., Vogelzang, N. J., ...

Background: Patients with hepatic or renal dysfunction are often treated with 5-fluorouracil (5-FU), but there are few data to confirm the safety of this practice. Patients and methods: Patients with...

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors (2001)

Eng, C., Mauer, A. M., Fleming, G. F., Bertucci, D., Rotmensch, J., Jacobs, R. H., ...

Background: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor (G-CSF) support. Moreover, there is concern...